Objective-Because of lack of evidence, we aimed to examine to what degree low-grade systemic inflammation and coronary heart disease (CHD) death shared common genetic and environmental substrates. Approach and Results-From the 41-year prospective National Heart, Lung, and Blood Institute Twin Study, we included 950 middle-aged male twins at baseline (1969)(1970)(1971)(1972)(1973)). Low-grade systemic inflammation was measured with plasma levels of interleukin-6 (IL-6) and C-reactive protein. Univariate and bivariate structural equation models were used, adjusted for a risk score for CHD death. The score-adjusted heritability was 19% for IL-6, 27% for C-reactive protein, and 22% for CHD death. The positive phenotypic correlation of IL-6 with CHD death (r adjusted =0.27; 95% confidence interval [CI], 0.08-0.43) was driven by additive genetic factors (contribution [relative contribution], 0.30 [111%]) but attenuated by unique environment (-0.03 [-11%])
T he role of the immune system and inflammatory pathways in the development of atherosclerotic disease is well established. 1 Circulating interleukin-6 (IL-6) and C-reactive protein (CRP) are biomarkers for systemic inflammation and are positively associated with coronary heart disease (CHD) risk. [2] [3] [4] [5] [6] [7] IL-6 is a proinflammatory cytokine, which stimulates hepatic production of CRP as an acute-phase protein, modulates cell adhesion, 8, 9 and promotes coagulation of platelets. 10 CRP may directly interact with atherosclerotic vessels or ischemic myocardium by activation of the complement system, thereby promoting inflammation and thrombosis. 11 Genetic factors contribute to plasma levels of IL-6 [12] [13] [14] [15] and CRP 12, 14, 16, 17 and CHD mortality. [18] [19] [20] [21] However, no previously published studies have explored the degree to which the correlation of IL-6 or CRP with CHD death is due to genetic or environmental factors.
We used a classical twin design with inclusion of monozygotic twins (MZ) and dizygotic twins (DZ) 22, 23 reared together to address this unclear area. MZ have identical genomes, whereas DZ share on average half of their genomes. If genetic factors influence a trait, MZ should be more similar than DZ. By comparing the similarity between MZ and DZ, we can quantify genetic and environmental contribution to traits. When 2 traits like inflammation and CHD death are studied, each trait can be influenced by its own set of genetic and environmental factors. The overlapping of the 2 sets of genetic and environmental factors may exist. A statistical modelbivariate Cholesky decomposition model-is used to assess if 2 traits are phenotypically correlated and the extent that these factors for the 2 traits are overlapped. 22 For example, a prior twin study found that white matter hyperintensities were correlated with physical function with a phenotypic correlation of -0.20. 24 The genetic factors for white matter hyperintensities and executive function were overlapped because the genetic correlation coefficient (r g ) was -0.24. 24 The negative value of this coefficient meant that the genetic factors augmenting white matter hyperintensities decreased executive function or vice versa. Similarly, this prior study also found that the unique environmental factors that were not shared between cotwins within a pair for each trait were overlapped because unique environmental correlation coefficient (r e ) was -0.22. 24 The negative value of the r e indicated that the unique environmental factors strengthening white matter hyperintensities weakened executive function or vice versa. In our classic twin study, we aimed to examine whether genetic and environmental factors explained the prospective correlation of IL-6 or CRP with CHD death in a population-based longitudinal study and to quantify the degree to which low-grade systemic inflammation and CHD deaths shared genetic and environmental substrates.
Materials and Methods
Materials and Methods are available in the online-only Supplement.
Results

Characteristics of the Study Population
During 41-year follow-up time, there were 143 CHD deaths (74 MZ and 69 DZ) among 950 twins (218 MZ and 227 DZ twin pairs, 31 unpaired MZ and 29 unpaired DZ twins). Twins who died of CHD had higher body mass index and diastolic and systolic blood pressure, higher plasma levels of total cholesterol and triglycerides, and a higher risk score than those not at baseline (Table 1) . Plasma levels of IL-6 were higher among twins who died of CHD (Table 1) . A flow diagram illustrated the conceptual framework of univariate and bivariate analyses ( Figure) .
Univariate Model Fitting
The AE model was the most parsimonious model for each of IL-6, CRP, and CHD death and was used to estimate the heritability ( Table 2) . The heritability was similar before and after adjustment for either baseline age or the risk score. Genetic components contributed to inflammation and CHD death. The risk score-adjusted heritability was 19% (95% confidence interval [CI], 2-34%) for IL-6, 27% (95% CI, 10-42%) for CRP, and 22% (95% CI, 0-45%) for CHD death during a 41-year follow-up period. Unique environmental factors explained the remaining variance.
Bivariate Model Fitting
The AE model was the best-fitting Cholesky model for the bivariate analyses (Table 3 ). The unadjusted prospective phenotypic correlation between IL-6 and CHD death (0.16; 95% CI, 0.03-0.28) was statistically significant. The age-adjusted and risk score-adjusted results were similar and were stronger than the unadjusted correlation. After adjustment for the risk score, a higher IL-6 level was significantly related to the higher CHD death risk (phenotypic correlation, 0.27; 95% CI, 0.08-0.43). The genetic contribution was large (relative contribution, 111%), and the unique environmental contribution was small (relative contribution, -11%; Table 3 ). The score-adjusted relative genetic contribution was >1, indicating that the positive part of the phenotypic correlation was driven by the genetic component, whereas the score-adjusted relative unique environmental contribution was <0, indicating that these factors contributed negatively to the adjusted phenotypic covariance.
We further examined whether the genetic component linking IL-6 to CHD death was common to both traits ( Table 3 ). Unadjusted r g and r e between IL-6 and CHD death were not statistically significant. After either age or score adjustment, r g was statistically significant, whereas r e was negative but remained nonsignificant. Both adjustments generated similar results. After adjusting for risk score, r g was 0.74 (95% CI, 0.21-1.00), whereas r e was -0.05 (95% CI, -0.35 to 0.25; Table 3 ). The score-adjusted genetic correlation suggested that the genetic origin of CHD death might be shared with the genetic origin of IL-6. Approximately 74% (ie, 0.74) of 0.22 of the heritability for CHD death ( Table 2 ) was shared with IL-6, but 26% (1-0.74) was independent of IL-6, supporting half of the genes influencing the 2 traits were shared. By contrast, 95% (1-0.05) of the unique environmental origin of CHD death was independent of IL-6.
The unadjusted, age-adjusted, and score-adjusted phenotypic correlations between CRP and CHD death were not statistically significant, to which the point estimate was >1 for relative genetic contribution and <0 for relative unique environmental contribution (Table 3) . Crude, age-adjusted, and score-adjusted r g and r e between CRP and CHD death were materially similar ( Table 3 ). The score-adjusted genetic correlation was moderate (r g =0.63). Approximately 63% (0.63) of 0.22 of the heritability for CHD death ( Table 2 ) was shared with CRP, but 37% (1-0.63) was independent of CRP, suggesting less than half of the genes influencing the 2 traits were shared. By contrast, 93% (1-0.07) of the unique environmental origin of CHD death was independent of CRP.
In the sensitivity analysis, similar results were obtained after additional adjustment for plasma sample collection examination ( Table I in the online-only Data Supplement). In another sensitivity analysis, the results did not change materially after excluding the twins with missing data on biomarkers (n=558; data not shown).
In the secondary analysis, we evaluated the degree to which low-grade systemic inflammation and CVD or all-cause mortality shared genetic and environmental factors ( Table II in the online-only Data Supplement). Result patterns were similar to those between IL-6 and CHD death, except the correlation between IL-6 and all-cause mortality ( Table II in the onlineonly Data Supplement). The score-adjusted point estimate of the relative genetic contribution to the correlation between IL-6 and all-cause mortality was 85%, whereas the relative unique environmental contribution was 15% ( Table II in 
Discussion
We found that both genetic and unique environmental factors explained variation in IL-6, CRP, and CHD death after adjustment for the composite risk score. The risk score-adjusted,
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MZ monozygotic twins statistically significant, and positive phenotypic correlation between IL-6 and CHD death was driven by genetic factors but attenuated by unique environmental factors. The risk score-adjusted genetic correlation between IL-6 and CHD death was moderate, positive, and statistically significant, whereas the risk score-adjusted unique environmental correlation was weakly negative and not statistically significant.
The risk score-adjusted phenotypic correlation between CRP and CHD death was not significant and was driven by genetic factors but attenuated by unique environmental factors. The heritability for IL-6 and CRP in our study was in the range of previously reported heritability for IL-6 (17% to 57%) [12] [13] [14] [15] and for CRP (20% to 61%). 12, 14, 16, 17 The heritability for CHD mortality in our study was lower than those in 2 prior prospective twin studies: 45% among male twins in a Danish twin study 21 and 57% 20 among male twins in a Swedish twin study. Our male twins were born between 1917 and 1927 and aged 58 to 94 years at death. The Danish male twins were born between 1870 and 1930 and aged 50 to 84 years at death and had a CHD mortality rate of 24%. 21 The Swedish male twins were born between 1886 and 1925 and aged 36 to >85 years at death with a 46% mortality rate of CHD. 20 Differences among twin populations including differences in the mortality rates of CHD, 23 birth years, and age at death 22 might explain differences in the heritability of CHD death among twin studies.
Our study was the prospective cohort study to quantify overall genetic and environmental contributions to the correlation of low-grade systemic inflammation with CHD death in a temporal sequence. We found that genetic factors contributed positively to the adjusted phenotypic correlation between IL-6 and CHD death but that unique environmental factors contributed negatively. Similar phenomena were observed in a previous study of the correlation between brachial pulse pressure and aortic pulse wave velocity 25 and another study of the correlation between white matter hyperintensities and physical function. 24 For example, the relative genetic contribution to the phenotypic correlation between brachial pulse pressure and aortic pulse wave velocity was 1.68, common environmental contribution was -0.43, and unique environmental contribution was -0.25. 25 In this scenario, environmental factors attenuated the phenotypic correlation between 2 traits due to genetic factors.
We found r g was greater than the phenotypic correlation coefficient for IL-6 and CRP with CHD death during the 41-year follow-up time. Similar phenomenon was found in a previous study of speech fluency, where the r g (0.75) was greater than the phenotypic correlation coefficient (0.72) between stuttering and nonfluency. 26 Such a phenomenon was plausible as they were not comparable. The r g but not phenotypic correlation measured the overlap extent of genes for 2 traits. The higher r g indicated a greater overlap extent. Our finding supported that *P values for comparing twins who died of CHD with those not. P values were derived from mixed models for continuous variables and generalized estimating equation logistic models for dichotomous variables to account for clustering within twin pairs. †Risk score contained information about age, smoking, body mass index, systolic blood pressure, diastolic blood pressure, total cholesterol, triglycerides, diabetes mellitus, low-density lipoprotein cholesterol, and high-density lipoprotein cholesterol. genetic factors shared between IL-6 and CHD death explained their phenotypic correlation.
Our study suggested that IL-6 and CHD death shared moderate genetic substrates, which augmented both traits. However, our twin study was unable to identify specific genes that simultaneously affected IL-6 and CHD death. Among previously published genetic studies that did not identify specific genes influencing both IL-6 and CHD death, 27-30 2 studies suggested that both traits shared common genes, 27, 30 but the other 2 studies did not. 28, 29 A prior study of a variant of the IL-6 gene found that the -572 G>C polymorphism influenced IL-6 gene transcription and modulated plasma levels of IL-6. 31 A meta-analysis of 27 studies found that -572 C allele was associated with a lower risk of CHD (including events and deaths) than -572 G allele. 27 Identification of genes other than -572 G>C, 27 which were common to IL-6 and CHD death, would require additional studies.
We could not rule out the existence of genetic factors shared between CRP and CHD death. Given the 95% CIs for genetic correlation between both traits, the risk score-adjusted genetic correlation could be as small as -0.07 or as large as 1.00. Prior studies of the existence of shared genes were inconsistent. 32, 33 In a case-control study, the single-nucleotide polymorphism rs2794521 (-717A>G) in the CRP gene promoter was independently associated with the presence of CHD among Chinese men 32 but not with fasting serum CRP levels. Men with AG and AA genotypes had a 6.8-fold higher risk of developing CHD than those with GG genotype. 32 The same single-nucleotide polymorphism was also correlated with the occurrence of myocardial infarction or thromboembolic stroke but not higher plasma levels of CRP among men in the prospective Physician's Health Study. 33 An animal experiment supported this single-nucleotide polymorphism in relation to CHD. 34 In this animal study, in vitro functional experiments showed that the A allele relative to the G allele increased transcriptional activity of the promoter of the CRP gene. 34 Our twin study was different from Mendelian randomization studies in the research aim and the methodology. In our twin study, plasma levels of inflammatory markers but not genetic factors were directly measured. We aimed to quantify the extent of shared genetic and environmental contributions to the relation between circulating inflammatory biomarkers and CHD. By contrast, in Mendelian randomization studies, genetic polymorphisms related to circulating inflammatory biomarker levels were directly measured as proxies for their circulating levels. The aim of Mendelian randomization studies was to evaluate the association between the circulating biomarker levels and CHD rather than understanding genetic mechanisms leading to disease. 35 These studies assumed the random allocation of gene alleles at conception and were heavily built on the logic reasoning: if inflammatory biomarker levels in circulation were causally linked to CHD, genetic variants influencing the biomarker levels should also be associated with CHD. 35, 36 For example, a Mendelian randomization meta-analysis of 9417 coronary artery disease patients and 15 982 controls aimed to test the correlation between circulating IL-6 concentrations with coronary artery disease risk. 36 IL-6 gene 174C/G polymorphism was used as the proxy for circulating IL-6 levels. 36 The CC/GC genotypes represented higher circulating IL-6 levels while GG represented lower levels. This was equivalent to the dichotomization of IL-6 levels. The dichotomization using the gene polymorphism might explain lack of a significant association between the 174 C/G and coronary artery disease risk because a significantly positive association between IL-6 levels and CHD risk was found when circulating IL-6 levels were directly used as the exposure variable and treated as a continuous variable. 36 Noticeably, in our study, we found that the higher circulating IL-6 levels were prospectively correlated to CHD death. Because of the natural limitations of the Mendelian randomization study including genetic instrument bias, where genetic variants as proxies for circulating biomarker levels were also called instrumental ‡r g and r e represented genetic and environmental correlation. 22 §Adjustment for risk score that contained information about age, smoking, body mass index, systolic blood pressure, diastolic blood pressure, total cholesterol, triglycerides, diabetes mellitus, low-density lipoprotein cholesterol, and high-density lipoprotein cholesterol.
variables, population stratification, pleiotropy and linkage disequilibrium, and the causal relation between circulating IL-6 levels and coronary artery disease could not be excluded. Such natural limitations could be avoided in our twin study.
In our twin study, genetic influences were statistically derived using the classic twin design. We found that substantial shared genetic materials contributed to the correlation between IL-6 levels and CHD death. This finding was the genetic evidence to support the causal relation between IL-6 levels and CHD. Mendelian randomization studies are aimed neither to provide genetic evidence for the causal link nor to quantify shared genetic factors. The presence of shared genetic determinants suggested the violation of the soundness of Mendelian randomization. Didelez and Sheehan 37 indicated that "if we know of a gene closely linked to the phenotype without direct effect on the disease, it can often be reasonably assumed that the gene is not itself associated with any confounding factors-a phenomenon called Mendelian randomization." Our twin study was not restricted to this prerequisite for the Mendelian randomization studies. Findings from Mendelian randomization studies would not be applied to the identification of the high-risk population via genetic variants, 35, 37 whereas those from our twin study should encourage the genetic identification of the high-risk population.
Another Mendelian randomization meta-analysis of pooled 25 458 CHD cases and 100 740 controls from 40 studies 38 attempted to address the causal link between the IL-6 receptor pathway and CHD. Although the T relative to C polymorphism of IL-6 receptor rs7529229 in the IL-6R gene was related to higher circulating concentrations of IL-6 and soluble IL-6 receptor but lower CRP levels, 38 it was not clearly defined whether the genetic variant was used as the proxy for circulating IL-6 levels alone, circulating soluble IL-6 receptor levels alone, circulating CRP levels alone, or for all 3 of circulating inflammatory biomarkers. As IL-6, soluble IL-6 receptor, and CRP levels were involved in the same pathway, the bias from potential genetic pleiotropy could not be excluded. This study reported that the T relative to C polymorphism of IL-6 receptor rs7529229 was associated with decreased odds of CHD events (including deaths). It was concluded that IL-6R signaling seemed to have a causal role in development of CHD. However, the ambiguous definition for the exposure variable raised a concern about interpretations of the study results, suggesting another possible limitation of Mendelian randomization studies.
Similarly, circulating CRP levels in relation to the CHD risk were also investigated in Mendelian randomization studies. Two large-scale Mendelian randomization meta-analyses failed to find statistically significant association of CRP gene variants in the CRP locus 39, 40 with CHD, although there was a significant association between CRP variants and circulating CRP concentrations. The authors did not exclude the causal association because of aforementioned natural limitations of Mendelian randomization studies.
There were limitations in our twin study. Our twins were white men, thus our results may not be generalized to women and other ethnic groups. We could not completely rule out the possibility of residual confounding, although several inflammation-related or CHD-related variables were adjusted for by using a risk score. The assumptions of classical twin studies in general also applied. In particular, common environmental influences were confounded with genetic nonadditivity, so it was possible that common environmental effects were underestimated. The correlation between environmental factors that influenced the traits was assumed to be equal for MZ and DZ twins. This assumption only applied to environmental factors that were not selected or elicited by the twins (eg, choice of diet as opposed to diet selected for them by their parents). It seems unlikely in the case of diet that parents of MZ twins would have systematically given more similar diets than parents of DZ twins. Because CHD was typically experienced later in life, during which time most twin pairs did not cohabit, it was likely that the shared environments of MZ pairs were not systematically more correlated than those of DZ pairs. The average blood sample storage period was 28 years in our study. Because of the limited samples, we did not evaluate the stability of plasma IL-6 and CRP. However, previous studies demonstrated the long-term stability of serum IL-6 41 and CRP. 42 In our bivariate analysis, we used the CHD death but not time-to-CHD death. To our best knowledge, there was not any established method for bivariate analysis in which ≥1 variable was time-to-event. Our finding still sheds light on the genetic and environmental contribution to the correlation of inflammation with CHD death risk.
Compared with Mendelian randomization studies and other traditional observational epidemiological studies, our twin study was advantageous in the direct evaluation of the phenotypic correlation between inflammatory biomarkers and CHD and understanding of genetic or environmental components underlying the correlation.
Our findings have clinical and preventive applications. Our results suggest that the therapeutic or interventional lowering of plasma levels of IL-6, either genetically or by medication, would be likely to reduce CHD death. Our findings encourage the identification of specific genetic variants that increased plasma IL-6 levels, which in turn would help clinicians to identify high-risk people for CHD death.
In conclusion, the positive phenotypic correlation between IL-6 and CHD death is driven by genetic factors but attenuated by unique environmental factors. Genetic factors that lead to high plasma levels of IL-6 also lead to CHD death. We could not exclude the possibility that IL-6 and CHD death share unique environmental factors.
To our knowledge, this study illustrates that low-grade inflammation measured by interleukin-6 and coronary heart death share genetic and unique environmental factors. Plasma interleukin-6 levels may be valuable for coronary heart disease mortality risk stratification and management. Our findings encourage the identification of specific genes that influence both plasma interleukin-6 levels and coronary heart death.
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